Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Ophthalmology

Looking Ahead: Long-Term Management and Monitoring

At a Glance

Long-term follow-up for chronic dacryoadenitis helps detect relapse, protect tear production and vision, and identify complications early. Monitoring may include eye exams, tear testing, imaging, and body checks when an underlying disease such as IgG4-related disease is present.

Once you have begun treatment for chronic dacryoadenitis, the focus shifts to long-term monitoring. Because many of the underlying causes—especially IgG4-related disease—are prone to returning, your care team will track your progress closely to catch any relapses early and prevent permanent damage to your vision or the ocular surface [1][2].

The Risk of Recurrence

A relapse is when the swelling or inflammation returns, often while you are tapering (lowering the dose) of your steroids [1]. The risk varies widely by diagnosis:

  • Idiopathic/Nonspecific Dacryoadenitis: Some patients experience a recurrence over five years. You are at a higher risk if the disease initially affected both eyes [3].
  • IgG4-Related Disease (IgG4-RD): This condition has a much higher relapse rate. A substantial portion of patients experience a recurrence after initially responding to treatment [1][4].

Contact your clinic promptly (routine) if you notice a gradual return of eyelid “heaviness,” increased eye irritation, or a palpable lump [5][6].
Seek SAME-DAY urgent ophthalmic or emergency care for new or rapidly worsening vision loss, reduced color vision, severe pain, rapidly increasing eye bulging, inability to close eyelids, fever with worsening redness, or severe headache.

Long-Term Complications to Watch For

Chronic inflammation can lead to changes in how your eye looks and functions:

  • Dry Eye Disease: Because the lacrimal gland is responsible for the watery part of your tears, chronic swelling or even the biopsy itself can reduce tear production [7][8]. This can lead to corneal erosions (scratches on the clear front of the eye) if left untreated [9][10]. Use clinician-recommended preservative-free lubricating drops consistently.
  • Structural Changes: Massive swelling of the gland can physically press on the eyeball, uncommonly causing chorioretinal folds (wrinkles in the back of the eye) [11].
  • Optic Neuropathy: In rare cases, particularly with IgG4-RD, inflammation can spread toward the optic nerve, which carries signals from the eye to the brain [12][13].

Why a Repeat Biopsy is Sometimes Necessary

If your symptoms don’t clear up with treatment, or if the swelling returns in a way that seems different from before, your specialist will reassess and may suggest a repeat biopsy [14].

This is not always because the first biopsy was “wrong,” but because some conditions, like lymphoma, can be difficult to distinguish from inflammation in their early stages [15]. In studies of patients selected for a second biopsy, a portion received a different diagnosis the second time around, identifying lymphoma or GPA [14][16]. A repeat biopsy ensures that a slow-growing cancer or specific disease hasn’t been missed [14][16].

Your Surveillance Schedule

Managing chronic dacryoadenitis requires individualized monitoring:

  1. Ophthalmic (Eye) Monitoring: Your visits will be more frequent during active disease or medication changes [17]. These visits should include:

    • Gland Palpation: Feeling the gland for new growth.
    • Vision and Eye Movement Tests: Checking for optic nerve pressure or muscle involvement.
    • Ocular Surface Testing: Using special dyes or paper strips (Schirmer test) to measure tear production [7][18].
    • Periodic Imaging: Repeat MRIs or CT scans may be ordered to monitor gland size if symptoms change [15][19].

  2. Systemic (Body) Monitoring: Especially if you have IgG4-RD or Sarcoidosis, your doctor may order imaging of your chest, abdomen, or pelvis based on your symptoms and baseline organ involvement [20][21]. Blood tests to track inflammatory markers or serum IgG4 levels can also provide helpful “trends” [22][23].

By staying consistent with this monitoring, you and your care team can manage flares quickly and protect your long-term eye health.

Common questions in this guide

How will chronic dacryoadenitis be monitored over time?
Follow-up may include an eye examination, feeling the lacrimal gland for new growth, vision and eye-movement checks, and tests that measure tear production. Repeat MRI or CT scans may be used if symptoms change. People with IgG4-related disease or sarcoidosis may also need imaging or blood tests to monitor other parts of the body.
What symptoms mean I should contact my eye clinic urgently?
A gradual return of eyelid heaviness, eye irritation, or a lump usually warrants a prompt call to your clinic. Seek same-day urgent eye or emergency care for new or rapidly worsening vision loss, reduced color vision, severe pain, rapidly increasing eye bulging, inability to close the eyelids, fever with worsening redness, or severe headache.
Why might I need another biopsy if my dacryoadenitis comes back?
A repeat biopsy may be recommended if treatment does not clear the swelling or if a returning lump looks different. Inflammation can sometimes resemble lymphoma, a cancer of immune cells, or granulomatosis with polyangiitis. A second biopsy can help identify a condition that was not apparent the first time.
How can I reduce dry-eye complications from chronic dacryoadenitis?
The lacrimal gland makes the watery part of tears, so chronic inflammation or a biopsy can reduce tear production. Use the preservative-free lubricating drops or other dry-eye treatment recommended by your clinician consistently. Report ongoing irritation or worsening dryness because untreated dryness can damage the clear surface of the eye.
Is chronic dacryoadenitis likely to come back?
The chance of relapse depends on the underlying diagnosis. Recurrence can occur in idiopathic or nonspecific dacryoadenitis and may be more likely when both eyes were affected, while IgG4-related disease has a higher relapse risk. A flare may appear while steroid treatment is being reduced.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific symptoms should prompt me to call the clinic versus heading to the emergency room?
  2. 2.Based on my confirmed diagnosis, what is my individualized plan for ophthalmic and systemic monitoring?
  3. 3.How can we proactively manage the health of my ocular surface and prevent severe dry eye complications?
  4. 4.If my symptoms don't fully resolve or if they return, at what point would we consider a repeat biopsy or new imaging?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series.

    Ebbo M, Patient M, Grados A, et al.

    Medicine 2017; (96(10)):e6205 doi:10.1097/MD.0000000000006205.

    PMID: 28272212
  2. 2

    Management of orbital IgG4-related disease.

    Glass LR, Freitag SK

    Current opinion in ophthalmology 2015; (26(6)):491-7 doi:10.1097/ICU.0000000000000204.

    PMID: 26367090
  3. 3

    Idiopathic Dacryoadenitis: Clinical Features, Histopathology, and Treatment Outcomes.

    Andrew NH, Kearney D, Sladden N, et al.

    American journal of ophthalmology 2016; (163()):148-153.e1 doi:10.1016/j.ajo.2015.11.032.

    PMID: 26701269
  4. 4

    Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease.

    Hong JW, Kang S, Song MK, et al.

    The British journal of ophthalmology 2018; (102(11)):1591-1595 doi:10.1136/bjophthalmol-2017-311519.

    PMID: 29420193
  5. 5

    Atypical presentation of Epstein-Barr virus infectious mononucleosis with bilateral dacryoadenitis in an elderly patient: a case report.

    Mahfoud N, Ali M, Abboud M

    Journal of medical case reports 2026; (20(1)).

    PMID: 42192474
  6. 6

    Clinical features and symptoms of IgG4-related ophthalmic disease: a multicenter study.

    Goto H, Ueda SI, Nemoto R, et al.

    Japanese journal of ophthalmology 2021; (65(5)):651-656 doi:10.1007/s10384-021-00847-3.

    PMID: 34146222
  7. 7

    Ocular Surface Evaluation in Immunoglobulin G4-Related Ophthalmic Disease.

    Lai KKH, Liao X, Aljufairi FMAA, et al.

    American journal of ophthalmology 2023; (256()):90-96 doi:10.1016/j.ajo.2023.07.031.

    PMID: 37544494
  8. 8

    Refractory Dry Eye Syndrome after Transconjunctival Excision of the Palpebral Lobe of the Lacrimal Gland.

    Lee YJ, Choi HS, Park SJ, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(6)) doi:10.3390/medicina57060608.

    PMID: 34208279
  9. 9

    Lacrimal gland development: From signaling interactions to regenerative medicine.

    Garg A, Zhang X

    Developmental dynamics : an official publication of the American Association of Anatomists 2017; (246(12)):970-980 doi:10.1002/dvdy.24551.

    PMID: 28710815
  10. 10

    Conjunctival Infiltration in a Child as a Rare Manifestation of IgG4-Related Disease.

    Qi SR, Hébert M, You E, et al.

    Cornea 2022; (41(4)):496-498 doi:10.1097/ICO.0000000000002773.

    PMID: 34050069
  11. 11

    Immunoglobulin G4-related dacyroadenitis presenting as bilateral chorioretinal folds from severely enlarged lacrimal glands.

    Kurokawa T, Hamano H, Muraki T, et al.

    American journal of ophthalmology case reports 2018; (9()):88-92 doi:10.1016/j.ajoc.2018.01.017.

    PMID: 29468226
  12. 12

    Cases with IgG4-related ophthalmic disease with mass lesions surrounding the optic nerve.

    Hamaoka S, Takahira M, Kawano M, et al.

    American journal of ophthalmology case reports 2022; (25()):101324 doi:10.1016/j.ajoc.2022.101324.

    PMID: 35146198
  13. 13

    The 2023 revised diagnostic criteria for IgG4-related ophthalmic disease.

    Takahira M, Goto H, Azumi A

    Japanese journal of ophthalmology 2024; (68(4)):293-301 doi:10.1007/s10384-024-01072-4.

    PMID: 39037515
  14. 14

    Repeated Lacrimal Gland Biopsies.

    Kaushik M, Vahdani K, Neumann I, et al.

    Ophthalmic plastic and reconstructive surgery 2024; (40(4)):440-444 doi:10.1097/IOP.0000000000002614.

    PMID: 38329425
  15. 15

    Magnetic resonance diffusion-weighted imaging in lacrimal gland lymphoma versus inflammation: A comparative study.

    Landau-Prat D, Shemesh R, Shalev D, et al.

    Indian journal of ophthalmology 2024; (72(10)):1448-1452 doi:10.4103/IJO.IJO_2109_23.

    PMID: 39331435
  16. 16

    Clinical, Radiological and Histopathological Features of Patients With Lacrimal Gland Enlargement.

    Jamshidian Tehrani M, Asadi Khameneh E, Pourseyed Iazarjani SZ, et al.

    Archives of Iranian medicine 2021; (24(12)):910-915 doi:10.34172/aim.2021.136.

    PMID: 35014239
  17. 17

    Grading Severity and Activity in Thyroid Eye Disease.

    Dolman PJ

    Ophthalmic plastic and reconstructive surgery 2018; (34(4S Suppl 1)):S34-S40 doi:10.1097/IOP.0000000000001150.

    PMID: 29952931
  18. 18

    Orbital Involvement and Ocular Surface Changes in IgG4-Related Systemic Disease.

    Kocabeyoglu S, Karadag O, Mocan MC, et al.

    Cornea 2016; (35(11)):1449-1453 doi:10.1097/ICO.0000000000000965.

    PMID: 27467041
  19. 19

    Relationship between dacryoadenitis subtype of idiopathic orbital inflammatory pseudotumor and paranasal sinusitis.

    Li J, Ge X, Ma JM

    International journal of ophthalmology 2016; (9(3)):444-7 doi:10.18240/ijo.2016.03.21.

    PMID: 27158618
  20. 20

    Bilateral IgG4-related ophthalmic disease: a strong indication for systemic imaging.

    Wu A, Andrew NH, McNab AA, Selva D

    The British journal of ophthalmology 2016; (100(10)):1409-11 doi:10.1136/bjophthalmol-2015-307437.

    PMID: 26719494
  21. 21

    Systemic Involvement in Immunoglobulin G4-Related Ophthalmic Disease.

    Lai KKH, Aljufairi FMAA, Sebastian JU, et al.

    Ocular immunology and inflammation 2024; (32(8)):1852-1858 doi:10.1080/09273948.2023.2280709.

    PMID: 38055933
  22. 22

    Long-Term Follow-Up in IgG4-Related Ophthalmic Disease: Serum IgG4 Levels and Their Clinical Relevance.

    Chou WY, Tsai CY, Tsai CC

    Journal of personalized medicine 2022; (12(12)) doi:10.3390/jpm12121963.

    PMID: 36556184
  23. 23

    Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study.

    Yuan Y, Meng F, Ren H, et al.

    Arthritis research & therapy 2022; (24(1)):80 doi:10.1186/s13075-022-02757-2.

    PMID: 35365184

This page is for informational purposes only and does not constitute medical advice. It explains long-term monitoring for chronic dacryoadenitis; follow your ophthalmologist’s plan and seek urgent care for sudden vision changes or severe symptoms.

Get notified when new evidence is published on chronic dacryoadenitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.